Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CCR6 | P51684 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241861 | 0.86 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL22646520 | 0.83 | OPRD1 (0.55) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL30913193 | 0.72 | SLC6A4 (0.38) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL30913192 | 0.72 | SLC6A4 (0.38) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL29282118 | 0.72 | SLC6A4 (0.38) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL9966015 | 0.70 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL260934 | 0.70 | KIF11 (0.47) | ALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL31084094 | 0.70 | ALDH1A1 (0.52) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL10389866 | 0.68 | OPRM1 (0.67) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL1802320 | 0.67 | CYP3A4 (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307426-B2 | Therapeutic compounds and compositions, and methods of use thereof | JAK2, JAK1, JAK3 | OPRM1 3325/4885OPRD1 3797/4885OPRK1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.